4.7 Article

Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPS™) SARS-CoV-2 Vaccine

期刊

VACCINES
卷 10, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/vaccines10071069

关键词

SARS-CoV-2 vaccine MAPS

向作者/读者索取更多资源

Despite the success of SARS-CoV-2 vaccines, the emergence of more resistant variants highlights the potential need for additional COVID-19 vaccines. The MAPS technology was used to engineer a novel vaccine targeting SARS-CoV-2, which generated robust immune responses and protection in nonhuman primates. This platform shows promise for developing vaccines that can include different variants.
Despite the remarkable success of SARS-CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen-Presenting System (MAPS) technology, in which proteins are presented on a polysaccharide polymer to induce antibody, Th1, Th17 and CD8+ T cell responses, to engineer a novel vaccine targeting SARS-CoV-2. This vaccine contains a fragment of the spike (S) protein receptor-binding domain (RBD) sequence of the original D614G strain and was used to immunize nonhuman primates (NHP) for assessment of immunological responses and protection against SARS-CoV-2 challenge. The SARS-CoV-2 MAPS vaccine generated robust neutralizing antibodies as well as Th1, Th17 and cytotoxic CD8 T-cell responses in NHPs. Furthermore, MAPS-immunized NHPs had significantly lower viral loads in the nasopharynx and lung compared to control animals. Taken together, these findings support the use of the MAPS platform to make a SARS-CoV-2 vaccine. The nature of the platform also could enable its use for the inclusion of different variants in a single vaccine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据